Identification of a unique gene expression signature that differentiates hepatocellular adenoma from well-differentiated hepatocellular carcinoma

American Journal of Surgical Pathology

Volumn 29, Issue 12, 2005, Pages 1600-1608

  Chen, Zong Ming E ^a   Crone, Kimberley G ^a   Watson, Mark A ^a   Pfeifer, John D ^a   Wang, Hanlin L ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gene expression microarray; Hepatocellular adenoma; Hepatocellular carcinoma

Indexed keywords

CLUSTERIN; CYCLINE; EPITHELIAL MEMBRANE ANTIGEN; ESTROGEN RECEPTOR; HOMEODOMAIN PROTEIN; PARAFFIN; PROTEIN DNAJ; SOMATOMEDIN A; TROPOMODULIN; TROPOMODULIN 1; UNCLASSIFIED DRUG; RNA;

ADULT; ARTICLE; CELL DIFFERENTIATION; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER ADENOMA; LIVER CELL CARCINOMA; MALE; MICROARRAY ANALYSIS; NEEDLE BIOPSY; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UNITED STATES; VALIDATION PROCESS; ADOLESCENT; AGED; CHI SQUARE DISTRIBUTION; CLUSTER ANALYSIS; COMPARATIVE STUDY; DNA MICROARRAY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; REPRODUCIBILITY;

ADENOMA, LIVER CELL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; CHI-SQUARE DISTRIBUTION; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NUCLEIC ACID HYBRIDIZATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA;

EID: 33644789090     PISSN: 01475185     EISSN: None     Source Type: Journal    
DOI: 10.1360/crad20050922     Document Type: Article

References (40)

1. Almendral JM, Huebsch D, Blundell PA, et al. Cloning and sequence of the human nuclear protein cyclin: homology with DNA-binding proteins. Proc Natl Acad Sci USA. 1987;84:1575-1579.
2. Anthony PP. Tumours and tumour-like lesions of the liver and biliary tract: aetiology, epidemiology and pathology. In: MacSween RNM, Burt AD, Portmann BC, et al, eds. Pathology of the Liver, 4th ed. London: Churchill Livingstone, 2002:713-715.
3. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis. 1999;19:271-285.
4. Breuhahn K, Vreden S, Haddad R, et al. Molecular profiling of human hepatocellular carcinoma defines mutually exclusive interferon regulation and insulin-like growth factor II overexpression. Cancer Res. 2004;64:6058-6064.
5. Cariani E, Lasserre C, Seurin D, et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res. 1988;48:6844-6849.
6. Cohen C, Lawson D, DeRose PB. Sex and androgenic steroid receptor expression in hepatic adenomas. Hum Pathol. 1998;29:1428-1432.
7. de Boer WB, Segal A, Frost FA, et al. Can CD34 discriminate between benign and malignant hepatocytic lesions in fine-needle aspirates and thin core biopsies? Cancer. 2000;90:273-278.
8. D'Errico A, Grigioni WF, Fiorentino M, et al. Expression of insulin-like growth factor II (IGF-II) in human hepatocellular carcinomas: an immunohistochemical study. Pathol Int. 1994;44:131-137.
9. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999;340:745-750.
10. Ferrell L. Liver pathology: cirrhosis, hepatitis, and primary liver tumors. Update and diagnostic problems. Mod Pathol. 2000;13:679-704.
11. Hill DA, O'Sullivan MJ, Zhu X, et al. Practical application of molecular genetic testing as an aid to the surgical pathologic diagnosis of sarcomas: a prospective study. Am J Surg Pathol. 2002;26:965-977.
12. Iizuka N, Oka M, Yamada-Okabe H, et al. Comparison of gene expression profiles between hepatitis B virus- and hepatitis C virus-infected hepatocellular carcinoma by oligonucleotide microarray data on the basis of a supervised learning method. Cancer Res. 2002;62:3939-3944.
13. Jones SE, Jomary C. Clusterin. Int J Biochem Cell Biol. 2002;34:427-431.
14. Kang YK, Hong SW, Lee H, et al. Overexpression of clusterin in human hepatocellular carcinoma. Hum Pathol. 2004;35:1340-1346.
15. Maga G, Hubscher U. Proliferating cell nuclear antigen (PCNA): a dancer with many partners. J Cell Sci. 2003;116:3051-3060.
16. Masood S, West AB, Barwick KW. Expression of steroid hormone receptors in benign hepatic tumors: an immunocytochemical study. Arch Pathol Lab Med. 1992;116:1355-1359.
17. Miskad UA, Yano Y, Nakaji M, et al. Histological study of PIVKA-II expression in hepatocellular carcinoma and adenomatous hyperplasia. Pathol Int. 2001;51:916-922.
18. Nakano A, Watanabe N, Nishizaki Y et al. Immunohistochemical studies on the expression of P-glycoprotein and p53 in relation to histological differentiation and cell proliferation in hepatocellular carcinoma. Hepatol Res. 2003;25:158-165.
19. Nardone G, Romano M, Calabro A, et al. Activation of fetal promoters of insulinlike growth factors II gene in hepatitis C virus-related chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Hepatology. 1996;23:1304-1312.
20. Nasarek A, Werner M, Nolte M, et al. Trisomy 1 and 8 occur frequently in hepatocellular carcinoma but not in liver cell adenoma and focal nodular hyperplasia: a fluorescence in situ hybridization study. Virchows Arch. 1995;427:373-378.
21. Neo SY, Leow CK, Vega VB, et al. Identification of discriminators of hepatoma by gene expression profiling using a minimal dataset approach. Hepatology. 2004;39:944-953.
22. Nolte M, Werner M, Nasarek A, et al. Expression of proliferation associated antigens and detection of numerical chromosome aberrations in primary human liver tumours: relevance to tumour characteristics and prognosis. J Clin Pathol. 1998;51:47-51.
23. Ojanguren I, Ariza A, Llatjós M, et al. Proliferating cell nuclear antigen expression in normal, regenerative, and neoplastic liver: a fine-needle aspiration cytology and biopsy study. Hum Pathol. 1993;24:905-908.
24. Osada S, Saji S, Kuno T. Clinical significance of combination study of apoptotic factors and proliferating cell nuclear antigen in estimating the prognosis of hepatocellular carcinoma. J Surg Oncol. 2004;85:48-54.
25. Park BC, Huh MH, Seo JH. Differential expression of transforming growth factor alpha and insulin-like growth factor II in chronic active hepatitis B, cirrhosis and hepatocellular carcinoma. J Hepatol. 1995;22:286-294.
26. Paunesku T, Mittal S, Protic M, et al. Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol. 2001;77:1007-1021.
27. Rooks JB, Ory HW, Ishak KG, et al. Epidemiology of hepatocellular adenoma: the role of oral contraceptive use. JAMA. 1979;242:644-648.
28. Rosai J. Liver tumors and tumorlike conditions. In: Rosai J, ed. Rosai and Ackerman's Surgical Pathology, 9th ed. Edinburgh: Mosby, 2004:993-995.
29. Saftoiu A, Ciurea T, Georgescu C, et al. Immunohistochemical assessment of proliferating cell nuclear antigen in primary hepatocellular carcinoma and dysplastic nodules. J Cell Mol Med. 2003;7:436-446.
30. Su Q, Liu YF, Zhang JF, et al. Expression of insulin-like growth factor II in hepatitis B, cirrhosis and hepatocellular carcinoma: its relationship with hepatitis B virus antigen expression. Hepatology. 1994;20:788-799.
31. Tanigawa N, Lu C, Mitsui T, et al. Quantitation of sinusoid-like vessels in hepatocellular carcinoma: its clinical and prognostic significance. Hepatology. 1997;26:1216-1223.
32. Tiniakos DG, Brunt EM. Proliferating cell nuclear antigen and Ki-67 labeling in hepatocellular nodules: a comparative study. Liver. 1999;19:58-68.
33. Torbenson M, Lee JH, Choti M, et al. Hepatic adenomas: analysis of sex steroid receptor status and the Wnt signaling pathway. Mod Pathol. 2002;15:189-196.
34. Trougakos IP, Gonos ES. Clusterin/apolipoprotein J in human aging and cancer. Int J Biochem Cell Biol. 2002;34:1430-1448.
35. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA. 2001;98:5116-5121.
36. Wilkens L, Bredt M, Flemming P, et al. Differentiation of liver cell adenomas from well-differentiated hepatocellular carcinomas by comparative genomic hybridization. J Pathol. 2001;193:476-482.
37. Wilkens L, Bredt M, Flemming P, et al. Diagnostic impact of fluorescence in situ hybridization in the differentiation of hepatocellular adenoma and well-differentiated hepatocellular carcinoma. J Mol Diagn. 2001;3:68-73.
38. Wilson MR, Easterbrook-Smith SB. Clusterin is a secreted mammalian chaperone. Trends Biochem Sci. 2000;25:95-98.
39. Yang GC, Yang GY, Tao LC. Distinguishing well-differentiated hepatocellular carcinoma from benign liver by the physical features of fine-needle aspirates. Mod Pathol. 2004;17:798-802.
40. Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med. 2003;9:416-423.